EASL-EASD-EASO代谢功能障碍相关脂肪性肝病(MASLD)管理临床实践指南
该联合指南更新了MASLD的定义、预防、筛查、诊断和治疗。建议对心血管代谢危险因素者采用FIB-4等无创试验阶梯式筛查进展性纤维化,治疗以生活方式干预和合并症管理为基础,非肝硬化MASH伴显著纤维化(≥2期)可考虑resmetirom。
要点
- MASLD定义为存在心血管代谢危险因素且无有害饮酒的脂肪性肝病。
- 心血管代谢危险因素、肝酶异常或影像学脂肪肝者应筛查纤维化,尤其2型糖尿病或肥胖者。
- 非肝硬化MASH伴显著纤维化(≥2期)可考虑resmetirom治疗,肝硬化期无靶向药物推荐。
核心结论
- MASLD管理包括生活方式干预、合并症优化管理及针对非肝硬化MASH伴显著纤维化者的resmetirom治疗。
研究设计与样本
- 欧洲肝脏研究学会(EASL)、欧洲糖尿病研究协会(EASD)和欧洲肥胖研究学会(EASO)联合制定的临床实践指南。
主要发现
- MASLD谱系包括脂肪变、代谢功能障碍相关脂肪性肝炎(MASH)、纤维化、肝硬化和MASH相关肝细胞癌(HCC)。
- resmetirom对脂肪性肝炎和纤维化显示组织学有效性,安全性和耐受性可接受。
关键数值与推荐
- 采用基于血液的评分(如FIB-4)及序贯影像技术(如瞬时弹性成像)的阶梯式方法适用于排除/确认进展性纤维化。
- 非肝硬化MASH且显著肝纤维化(≥2期)的成人,若当地批准且取决于标签,应考虑resmetirom治疗。
- 目前肝硬化阶段无可推荐的MASH靶向药物治疗。
临床怎么用
- 对有心血管代谢危险因素、肝酶异常和/或影像学肝脂肪变者,尤其2型糖尿病或肥胖伴额外代谢危险因素者,应应用无创试验进行MASLD伴纤维化的病例发现策略。
- 成人MASLD建议生活方式干预(减重、饮食改变、体育锻炼、不鼓励饮酒)及合并症优化管理,包括酌情使用肠促胰岛素类药物(如司美格鲁肽、替尔泊肽)治疗2型糖尿病或肥胖。
- 减重手术是MASLD伴肥胖者的选项之一。
- MASH相关肝硬化管理包括代谢药物调整、营养咨询、门静脉高压和HCC监测,失代偿肝硬化可行肝移植。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake. The spectrum of MASLD includes steatosis, metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), fibrosis, cirrhosis and MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis and treatment for MASLD. Case-finding strategies for MASLD with liver fibrosis, using non-invasive tests, should be applied in individuals with cardiometabolic risk factors, abnormal liver enzymes, and/or radiological signs of hepatic steatosis, particularly in the presence of type 2 diabetes (T2D) or obesity with additional metabolic risk factor(s). A stepwise approach using blood-based scores (such as FIB-4) and, sequentially, imaging techniques (such as transient elastography) is suitable to rule-out/in advanced fibrosis, which is predictive of liver-related outcomes. In adults with MASLD, lifestyle modification - including weight loss, dietary changes, physical exercise and discouraging alcohol consumption - as well as optimal management of comorbidities - including use of incretin-based therapies (e.g. semaglutide, tirzepatide) for T2D or obesity, if indicated - is advised. Bariatric surgery is also an option in individuals with MASLD and obesity. If locally approved and dependent on the label, adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2) should be considered for a MASH-targeted treatment with resmetirom, which demonstrated histological effectiveness on steatohepatitis and fibrosis with an acceptable safety and tolerability profile. No MASH-targeted pharmacotherapy can currently be recommended for the cirrhotic stage. Management of MASH-related cirrhosis includes adaptations of metabolic drugs, nutritional counselling, surveillance for portal hypertension and HCC, as well as liver transplantation in decompensated cirrhosis.
引用
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024. PMID: 38851997. doi:10.1016/j.jhep.2024.04.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。